Event-Driven Stocks

Shattuck Labs, Inc.

STTKNasdaq

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 4 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$1.0M$5.7M$1.7M$652,000$30.0M$9.9M
Operating income−$51.5M−$80.6M−$92.0M−$103.3M−$45.3M−$36.9M
Net income−$48.8M−$75.4M−$87.3M−$101.9M−$45.0M−$36.6M
Total assets$91.0M$91.0M$159.6M$205.3M$298.6M$349.0M
Total liabilities$8.6M$11.4M$14.9M$29.2M$26.8M$39.1M
Equity$82.4M$79.6M$144.7M$176.2M$271.8M$309.9M
EPS (diluted)$-0.70$-1.49$-2.05$-2.41$-1.07$-2.36
Shares out.47.9M47.5M42.4M42.4M41.8M41.8M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−5150.8%
Net margin
−4880.9%
Return on equity
−59.2%
Return on assets
−53.6%
Return on capital (ROCE)
−61.3%
Liabilities / assets
9.5%
Debt / equity
0.10×
Book value / share
$1.72
Revenue growth (YoY)
−82.5%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-3.77distress
Accruals / assets
−9.8%clean
Piotroski F-Score
4/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
42
/ 100
Profitability 0Growth 0Catalyst 67Earnings quality 67Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 4 warning● 2 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Revenue declined year-over-year
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20261.3M2.1-6.7%
Apr 30, 20261.4M3.3+6.0%
Apr 15, 20261.3M2.9-8.9%
Mar 31, 20261.5M2.3-7.2%
Mar 13, 20261.6M1.7-1.6%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.